MA49840A - Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) - Google Patents
Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)Info
- Publication number
- MA49840A MA49840A MA049840A MA49840A MA49840A MA 49840 A MA49840 A MA 49840A MA 049840 A MA049840 A MA 049840A MA 49840 A MA49840 A MA 49840A MA 49840 A MA49840 A MA 49840A
- Authority
- MA
- Morocco
- Prior art keywords
- prmt5
- inhibitors
- protein arginine
- arginine methyltransferase
- selective protein
- Prior art date
Links
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 title 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543141P | 2017-08-09 | 2017-08-09 | |
| US201862630581P | 2018-02-14 | 2018-02-14 | |
| US201862664442P | 2018-04-30 | 2018-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49840A true MA49840A (fr) | 2020-06-17 |
Family
ID=63405398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049840A MA49840A (fr) | 2017-08-09 | 2018-08-09 | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10570140B2 (fr) |
| EP (2) | EP3665179B1 (fr) |
| JP (1) | JP2020530496A (fr) |
| KR (1) | KR20200036922A (fr) |
| CN (1) | CN111527099B (fr) |
| AU (1) | AU2018313910B2 (fr) |
| BR (1) | BR112020002736A2 (fr) |
| CA (1) | CA3072439A1 (fr) |
| DK (1) | DK3665179T3 (fr) |
| ES (1) | ES2885180T3 (fr) |
| IL (1) | IL272519B (fr) |
| MA (1) | MA49840A (fr) |
| MX (1) | MX2020001598A (fr) |
| PL (1) | PL3665179T3 (fr) |
| PT (1) | PT3665179T (fr) |
| UA (1) | UA126481C2 (fr) |
| WO (1) | WO2019032859A1 (fr) |
| ZA (1) | ZA202000773B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49840A (fr) * | 2017-08-09 | 2020-06-17 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| CA3092357A1 (fr) * | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Inhibiteurs selectifs de la proteine arginine methyltransferase 5 (prmt5) |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CA3108388A1 (fr) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| WO2020033285A1 (fr) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| EP3947387B1 (fr) * | 2019-03-25 | 2024-10-23 | California Institute Of Technology | Inhibiteurs de prmt5 et leurs utilisations |
| WO2020206299A1 (fr) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 |
| WO2020206289A1 (fr) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 |
| KR20220016194A (ko) * | 2019-05-30 | 2022-02-08 | 앤젝스 파마수티컬, 인크. | Prmt5 억제제로서의 헤테로시클릭 화합물 |
| CA3154566A1 (fr) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics Incorporated | Inhibiteurs selectifs de la proteine arginine methyltransferase 5 (prmt5) |
| CN115298179A (zh) * | 2019-10-21 | 2022-11-04 | 埃克森特治疗公司 | Mettl3调节剂 |
| GEP20247638B (en) * | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| EP4214213A1 (fr) | 2020-09-21 | 2023-07-26 | Prelude Therapeutics, Incorporated | Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques |
| US20220251088A1 (en) * | 2020-12-10 | 2022-08-11 | Prelude Therapeutics, Incorporated | Processes for Making PRMT5 Inhibitors |
| LT4263545T (lt) * | 2020-12-16 | 2026-07-27 | Amgen Inc. | Prmt5 inhibitoriai |
| IL316942A (en) | 2020-12-18 | 2025-01-01 | Prelude Therapeutics Inc | CDK inhibitors and their use as drugs |
| CN117157297B (zh) * | 2021-07-20 | 2026-06-16 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| US20230181589A1 (en) * | 2021-12-03 | 2023-06-15 | The Trustees Of Indiana University | Prmt5 inhibitors for ocular therapy |
| US11939340B2 (en) | 2022-01-21 | 2024-03-26 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| US20230257394A1 (en) | 2022-02-03 | 2023-08-17 | Prelude Therapeutics, Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| WO2023172957A1 (fr) | 2022-03-09 | 2023-09-14 | Prelude Therapeutics, Incorporated | Inhibiteurs de cdk thiazole-pyrimidine et leur utilisation en tant que produits pharmaceutiques |
| IL315671A (en) | 2022-03-23 | 2024-11-01 | Prelude Therapeutics Inc | Polymorphic compounds and their uses |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| US20240150340A1 (en) | 2022-10-06 | 2024-05-09 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| US20240352029A1 (en) | 2023-04-14 | 2024-10-24 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| CN116554194A (zh) * | 2023-05-23 | 2023-08-08 | 江苏八巨药业有限公司 | 一种卡培他滨中间体的合成方法 |
| WO2025064402A1 (fr) * | 2023-09-22 | 2025-03-27 | St. Jude Children's Research Hospital, Inc. | Méthode de traitement de la drépanocytose par ciblage des cellules sénescentes |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (fr) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Greffon vasculaire intraluminal |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| DE102010060118B4 (de) * | 2010-10-22 | 2025-09-25 | Röhm Gmbh | Stirnseitenmitnehmer |
| EP2646454B1 (fr) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci |
| EP3238722B1 (fr) * | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Formes solides d'isoquinolinones |
| WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
| US9604930B2 (en) * | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US9133189B2 (en) * | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP6510485B2 (ja) * | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| WO2015200680A2 (fr) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| EP3160466A4 (fr) * | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2016066582A1 (fr) | 2014-10-28 | 2016-05-06 | Bci Pharma | Inhibiteurs de la nucléoside kinase |
| KR101719881B1 (ko) * | 2014-12-22 | 2017-03-24 | 삼성전기주식회사 | 렌즈 모듈 |
| EA031895B1 (ru) * | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| WO2017218802A1 (fr) | 2016-06-15 | 2017-12-21 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018065365A1 (fr) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
| WO2018075601A1 (fr) | 2016-10-18 | 2018-04-26 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018085818A1 (fr) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018085833A2 (fr) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018152548A1 (fr) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018152501A1 (fr) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018160824A1 (fr) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2018160855A1 (fr) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| MA49840A (fr) * | 2017-08-09 | 2020-06-17 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| EP3700906A1 (fr) | 2017-10-26 | 2020-09-02 | Prelude Therapeutics, Incorporated | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| WO2020033285A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
-
2018
- 2018-08-09 MA MA049840A patent/MA49840A/fr unknown
- 2018-08-09 WO PCT/US2018/046057 patent/WO2019032859A1/fr not_active Ceased
- 2018-08-09 DK DK18760136.4T patent/DK3665179T3/da active
- 2018-08-09 AU AU2018313910A patent/AU2018313910B2/en not_active Ceased
- 2018-08-09 US US16/059,909 patent/US10570140B2/en active Active
- 2018-08-09 JP JP2020530436A patent/JP2020530496A/ja not_active Ceased
- 2018-08-09 BR BR112020002736-7A patent/BR112020002736A2/pt not_active Application Discontinuation
- 2018-08-09 MX MX2020001598A patent/MX2020001598A/es unknown
- 2018-08-09 KR KR1020207006384A patent/KR20200036922A/ko not_active Ceased
- 2018-08-09 PT PT187601364T patent/PT3665179T/pt unknown
- 2018-08-09 ES ES18760136T patent/ES2885180T3/es active Active
- 2018-08-09 UA UAA202000927A patent/UA126481C2/uk unknown
- 2018-08-09 CA CA3072439A patent/CA3072439A1/fr active Pending
- 2018-08-09 EP EP18760136.4A patent/EP3665179B1/fr active Active
- 2018-08-09 EP EP21178139.8A patent/EP3939986A1/fr not_active Withdrawn
- 2018-08-09 CN CN201880065979.7A patent/CN111527099B/zh not_active Expired - Fee Related
- 2018-08-09 PL PL18760136T patent/PL3665179T3/pl unknown
-
2020
- 2020-01-16 US US16/744,771 patent/US11078205B2/en not_active Expired - Fee Related
- 2020-02-05 ZA ZA2020/00773A patent/ZA202000773B/en unknown
- 2020-02-06 IL IL272519A patent/IL272519B/en unknown
- 2020-08-05 US US16/985,643 patent/US11208416B2/en not_active Expired - Fee Related
-
2021
- 2021-11-18 US US17/529,781 patent/US20220153747A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10570140B2 (en) | 2020-02-25 |
| JP2020530496A (ja) | 2020-10-22 |
| EP3939986A1 (fr) | 2022-01-19 |
| CA3072439A1 (fr) | 2019-02-14 |
| US20200148692A1 (en) | 2020-05-14 |
| IL272519B (en) | 2022-05-01 |
| EP3665179A1 (fr) | 2020-06-17 |
| US11078205B2 (en) | 2021-08-03 |
| WO2019032859A1 (fr) | 2019-02-14 |
| EP3665179B1 (fr) | 2021-06-09 |
| ZA202000773B (en) | 2022-07-27 |
| US20190048014A1 (en) | 2019-02-14 |
| IL272519A (en) | 2020-03-31 |
| AU2018313910A1 (en) | 2020-03-05 |
| MX2020001598A (es) | 2020-10-28 |
| CN111527099B (zh) | 2024-03-22 |
| KR20200036922A (ko) | 2020-04-07 |
| PL3665179T3 (pl) | 2021-11-29 |
| UA126481C2 (uk) | 2022-10-12 |
| US20220153747A1 (en) | 2022-05-19 |
| DK3665179T3 (da) | 2021-08-16 |
| BR112020002736A2 (pt) | 2020-07-28 |
| AU2018313910B2 (en) | 2022-12-08 |
| US11208416B2 (en) | 2021-12-28 |
| ES2885180T3 (es) | 2021-12-13 |
| PT3665179T (pt) | 2021-09-10 |
| US20200361946A1 (en) | 2020-11-19 |
| CN111527099A (zh) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272519B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| MA52005A (fr) | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) | |
| EP3952874A4 (fr) | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 | |
| EP3679031A4 (fr) | Inhibiteurs de la liaison protéine wdr5-protéine | |
| EP3833355A4 (fr) | Inhibiteurs de prmt5 | |
| EP3518934A4 (fr) | Inhibiteurs de l'adénosine 5'-nucléotidase | |
| EP3423451A4 (fr) | Inhibiteurs de la liaison protéine wdr5-protéine | |
| MA47323A (fr) | Protéines de liaison icos | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| EP3946352A4 (fr) | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 | |
| EP3654875C0 (fr) | Système d'arthrodèse d'une articulation | |
| DK3319939T3 (da) | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer | |
| EP4063358C0 (fr) | Inhibiteurs de l'histone méthyltransférase | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| MA50908A (fr) | Formulations de protéines de fusion vegfr-fc | |
| EP3706747A4 (fr) | Inhibiteurs de prmt5 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3711510C0 (fr) | Système de substitution du tabac | |
| EP3746430A4 (fr) | Inhibiteurs de protéine arginine déiminases | |
| IL287309A (en) | Electrosurgical system | |
| IL287160A (en) | Electrosurgical system | |
| DK3737402T5 (da) | Modificeret protein | |
| DK3574100T3 (da) | Cellefrit proteinsyntesesystem | |
| EP3833669A4 (fr) | Inhibiteurs de prmt5 | |
| EP3833668A4 (fr) | Inhibiteurs de prmt5 |